Ubenimex (INN), also known more commonly as bestatin, is a competitive, reversible protease inhibitor. It is being studied for use in the treatment of acute myelocytic leukemia. It is derived from Streptomyces olivoreticuli. Ubenimex has been found to inhibit the enzymatic degradation of oxytocin, vasopressin, enkephalins, and various other peptides and compounds.

The global Ubenimex market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Ubenimex volume and value at global level, regional level and company level. From a global perspective, this report represents overall Ubenimex market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Ubenimex in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Ubenimex manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Eiger BioPharmaceuticals
Nippon Kayaku
Chengdu Easton Biopharmaceuticals
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Tablet
Capsules

Segment by Application
Treatment of acute myelocytic leukemia
others